Q&A: FDA-Authorized Digital Therapeutics for Anxiety and Depression – What the Primary Documents Show

Q&A: FDA-Authorized Digital Therapeutics for Anxiety and Depression – What the Primary Documents Show

The U.S. Food and Drug Administration has authorized prescription digital therapeutics (PDTs) as Class II medical devices for certain behavioral health conditions since 2017. These software tools deliver structured therapeutic interventions and require a physician’s prescription. Primary FDA and NIH documents indicate several authorized PDTs address conditions such as substance use disorder, insomnia, and ADHD—issues that frequently overlap with anxiety, depression, and lower treatment-seeking rates among men. This Q&A examines what the regulatory records and research priorities actually state.

Which PDTs has the FDA authorized for mental or behavioral health conditions relevant to men?

The FDA authorized its first PDT, reSET from Pear Therapeutics, on September 14, 2017, for substance use disorder via the de novo pathway [2]. Agency documents classify all PDTs as Class II medical devices that undergo evaluation for safety, efficacy, and clinical outcomes and must be prescribed with physician oversight [1]. As of 2024, more than 10 PDTs have received authorization; several target behavioral health indications including insomnia (Somryst) and ADHD (EndeavorRx), conditions linked to the broader mental health burden documented in male populations [1][4].

What is NIH’s position on the evidence base and research gaps for digital therapeutics in mental health?

NIH and NIMH materials identify the development and rigorous testing of technology-based interventions as a research priority aimed at reducing mental health disparities [3]. The documents note that men are less likely to seek traditional care and state that high-quality randomized trials plus real-world evidence are required to assess efficacy, safety, and adherence. FDA and NIH records consistently describe PDTs as tools that must demonstrate measurable clinical benefit before wider use.

Are there gender-specific considerations or male-focused trials for PDTs according to primary sources?

Primary sources show no PDT carries FDA labeling exclusively for male patients; all available evidence derives from mixed-gender trials [1][4]. ClinicalTrials.gov listings document ongoing studies of digital therapeutics in mental health, yet completed large-scale male-only trials remain limited. NIH releases highlight that long-term real-world effectiveness data specific to male populations continues to represent a gap in the current evidence base [3].

How are PDTs described in relation to mental health care in regulatory guidance?

FDA documents state that authorized PDTs are intended to complement, not replace, standard care including psychotherapy and pharmacotherapy [1]. The regulatory pathway requires physician involvement, and NIH materials frame these interventions as one potential route to improve access and engagement for populations that underutilize conventional services, provided they rest on solid randomized evidence [3].

What this means

The records show that FDA-authorized PDTs exist for several behavioral health areas connected to men’s mental health experiences and are regulated with the same expectations for safety and effectiveness applied to other Class II devices. NIH priorities suggest these technologies may help address access barriers for men, yet the primary sources emphasize that the evidence base still depends on continued rigorous testing and that real-world data specific to male populations remain limited. The documents present an evolving picture rather than a finished one.

Limitations

No PDTs carry FDA labeling exclusively for male patients; evidence is derived from mixed-gender trials. Long-term real-world effectiveness data specific to male populations remain limited per NIH statements. The field evolves rapidly; new authorizations or label expansions may occur after 2024. ClinicalTrials.gov shows ongoing trials but few completed large-scale male-only studies.